Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1651 to 1665 of 8909 results

  1. Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab (TA612)

    Evidence-based recommendations on neratinib (Nerlynx) for extended adjuvant treatment of hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-positive early stage breast cancer in adults.

  2. Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis (TA624)

    Evidence-based recommendations on peginterferon beta-1a (Plegridy) for treating relapsing–remitting multiple sclerosis in adults.

  3. Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer (TA632)

    Evidence-based recommendations on trastuzumab emtansine (Kadcyla) for human epidermal growth factor receptor 2 (HER2)-positive early breast cancer in adults who have residual invasive disease in the breast or lymph nodes after neoadjuvant taxane-based and HER2-targeted therapy.

  4. Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer (TA639)

    Evidence-based recommendations on atezolizumab (Tecentriq) with nab-paclitaxel for triple-negative, unresectable, PD-L1-positive, locally advanced or metastatic breast cancer in adults who have not had chemotherapy for metastatic disease.

  5. Anakinra for treating Still's disease (TA685)

    Evidence-based recommendations on anakinra (Kineret) for treating adult-onset Still’s disease and systemic juvenile idiopathic arthritis in people 8 months and older.

  6. Nivolumab for adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancer (TA746)

    Evidence-based recommendations on nivolumab (Opdivo) as a possible treatment for completely resected oesophageal or gastro-oesophageal junction cancer in adults.

  7. Regorafenib for treating advanced gastrointestinal stromal tumours [ID1056]

    In development Reference number: GID-TA10089 Expected publication date:  15 November 2017

  8. NY-ESO-1 T-cells for treating synovial sarcoma ID1286

    In development Reference number: GID-TA10205 Expected publication date: TBC

  9. Exploratory economic modelling of SARS-CoV-2 viral detection point of care tests and serology tests

    In development Reference number: GID-DG10038 Expected publication date: TBC

  10. Managing symptoms with an uncertain cause

    Awaiting development Reference number: GID-QS10103 Expected publication date: TBC

  11. Safe prescribing and withdrawal management of prescribed drugs associated with dependence and withdrawal

    Awaiting development Reference number: GID-QS10106 Expected publication date: TBC

  12. Indoor air quality at home

    In development Reference number: GID-QS10113 Expected publication date: TBC

  13. Vulnerable populations: strategies for tackling inequalities

    Awaiting development Reference number: GID-QS10124 Expected publication date: TBC

  14. Pelvic floor dysfunction

    Awaiting development Reference number: GID-QS10129 Expected publication date: TBC

  15. Pernicious anaemia

    Awaiting development Reference number: GID-QS10130 Expected publication date: TBC